-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$52.33169.6% Upside
AnaptysBio, Inc. Frequently Asked Questions
-
What analysts cover AnaptysBio, Inc.?
AnaptysBio, Inc. has been rated by research analysts at Guggenheim, Piper Sandler, New Street, Truist Financial, Leerink Partners, J.P. Morgan in the past 90 days.